---
document_datetime: 2025-12-29 11:10:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/neurobloc.html
document_name: neurobloc.html
version: success
processing_time: 0.2859056
conversion_datetime: 2025-12-30 00:16:07.895823
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# NeuroBloc

[RSS](/en/individual-human-medicine.xml/65449)

##### Withdrawn

This medicine's authorisation has been withdrawn

botulinum toxin type B Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 9 December 2022, the European Commission withdrew the marketing authorisation for NeuroBloc (botulinum toxin type B) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sloan Pharma S.a.r.l, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

NeuroBloc was granted marketing authorisation in the EU on 22 January 2001 for the treatment of cervical dystonia in adults. Therapeutic alternatives are available throughout the European Union. Patients taking Neurobloc or participating in a clinical trial are advised to consult their physician.

The European Public Assessment Report (EPAR) for NeuroBloc (SRD) is updated to indicate that the marketing authorisation is no longer valid.

NeuroBloc : EPAR - Summary for the public

English (EN) (658.71 KB - PDF)

**First published:** 01/02/2008

**Last updated:** 04/05/2023

[View](/en/documents/overview/neurobloc-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-800)

български (BG) (731.42 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/bg/documents/overview/neurobloc-epar-summary-public_bg.pdf)

español (ES) (657.88 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/es/documents/overview/neurobloc-epar-summary-public_es.pdf)

čeština (CS) (716.1 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/cs/documents/overview/neurobloc-epar-summary-public_cs.pdf)

dansk (DA) (656.99 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/da/documents/overview/neurobloc-epar-summary-public_da.pdf)

Deutsch (DE) (659.61 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/de/documents/overview/neurobloc-epar-summary-public_de.pdf)

eesti keel (ET) (656.6 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/et/documents/overview/neurobloc-epar-summary-public_et.pdf)

ελληνικά (EL) (767.68 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/el/documents/overview/neurobloc-epar-summary-public_el.pdf)

français (FR) (658.23 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/fr/documents/overview/neurobloc-epar-summary-public_fr.pdf)

hrvatski (HR) (679.14 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/hr/documents/overview/neurobloc-epar-summary-public_hr.pdf)

italiano (IT) (656.62 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/it/documents/overview/neurobloc-epar-summary-public_it.pdf)

latviešu valoda (LV) (722.82 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/lv/documents/overview/neurobloc-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (681.97 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/lt/documents/overview/neurobloc-epar-summary-public_lt.pdf)

magyar (HU) (709.87 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/hu/documents/overview/neurobloc-epar-summary-public_hu.pdf)

Malti (MT) (718.09 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/mt/documents/overview/neurobloc-epar-summary-public_mt.pdf)

Nederlands (NL) (660.94 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/nl/documents/overview/neurobloc-epar-summary-public_nl.pdf)

polski (PL) (714.79 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/pl/documents/overview/neurobloc-epar-summary-public_pl.pdf)

português (PT) (658.13 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/pt/documents/overview/neurobloc-epar-summary-public_pt.pdf)

română (RO) (688.79 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/ro/documents/overview/neurobloc-epar-summary-public_ro.pdf)

slovenčina (SK) (715.32 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/sk/documents/overview/neurobloc-epar-summary-public_sk.pdf)

slovenščina (SL) (708.49 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/sl/documents/overview/neurobloc-epar-summary-public_sl.pdf)

Suomi (FI) (656.75 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/fi/documents/overview/neurobloc-epar-summary-public_fi.pdf)

svenska (SV) (657.42 KB - PDF)

**First published:**

01/02/2008

**Last updated:**

04/05/2023

[View](/sv/documents/overview/neurobloc-epar-summary-public_sv.pdf)

## Product information

NeuroBloc : EPAR - Product Information

English (EN) (1.07 MB - PDF)

**First published:** 25/08/2009

**Last updated:** 04/05/2023

[View](/en/documents/product-information/neurobloc-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-674)

български (BG) (1.97 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/bg/documents/product-information/neurobloc-epar-product-information_bg.pdf)

español (ES) (1.06 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/es/documents/product-information/neurobloc-epar-product-information_es.pdf)

čeština (CS) (1.65 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/cs/documents/product-information/neurobloc-epar-product-information_cs.pdf)

dansk (DA) (1.07 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/da/documents/product-information/neurobloc-epar-product-information_da.pdf)

Deutsch (DE) (1.06 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/de/documents/product-information/neurobloc-epar-product-information_de.pdf)

eesti keel (ET) (1.04 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/et/documents/product-information/neurobloc-epar-product-information_et.pdf)

ελληνικά (EL) (1.93 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/el/documents/product-information/neurobloc-epar-product-information_el.pdf)

français (FR) (1.04 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/fr/documents/product-information/neurobloc-epar-product-information_fr.pdf)

hrvatski (HR) (1.15 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/hr/documents/product-information/neurobloc-epar-product-information_hr.pdf)

íslenska (IS) (1.05 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/is/documents/product-information/neurobloc-epar-product-information_is.pdf)

italiano (IT) (1.04 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/it/documents/product-information/neurobloc-epar-product-information_it.pdf)

latviešu valoda (LV) (1.65 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/lv/documents/product-information/neurobloc-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.19 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/lt/documents/product-information/neurobloc-epar-product-information_lt.pdf)

magyar (HU) (1.7 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/hu/documents/product-information/neurobloc-epar-product-information_hu.pdf)

Malti (MT) (1.7 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/mt/documents/product-information/neurobloc-epar-product-information_mt.pdf)

Nederlands (NL) (1.1 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/nl/documents/product-information/neurobloc-epar-product-information_nl.pdf)

norsk (NO) (1.05 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/no/documents/product-information/neurobloc-epar-product-information_no.pdf)

polski (PL) (1.66 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/pl/documents/product-information/neurobloc-epar-product-information_pl.pdf)

português (PT) (1.07 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/pt/documents/product-information/neurobloc-epar-product-information_pt.pdf)

română (RO) (1.23 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/ro/documents/product-information/neurobloc-epar-product-information_ro.pdf)

slovenčina (SK) (1.62 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/sk/documents/product-information/neurobloc-epar-product-information_sk.pdf)

slovenščina (SL) (1.64 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/sl/documents/product-information/neurobloc-epar-product-information_sl.pdf)

Suomi (FI) (1.04 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/fi/documents/product-information/neurobloc-epar-product-information_fi.pdf)

svenska (SV) (1.05 MB - PDF)

**First published:**

25/08/2009

**Last updated:**

04/05/2023

[View](/sv/documents/product-information/neurobloc-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0107 04/03/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

NeuroBloc : EPAR - All Authorised presentations

English (EN) (629.2 KB - PDF)

**First published:** 01/06/2008

**Last updated:** 04/05/2023

[View](/en/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_en.pdf)

[Other languages (10)](#file-language-dropdown-181)

español (ES) (628.95 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/es/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_es.pdf)

dansk (DA) (631.64 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/da/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (633.36 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/de/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_de.pdf)

ελληνικά (EL) (667.92 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/el/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_el.pdf)

français (FR) (629.44 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/fr/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (625.83 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/it/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_it.pdf)

Nederlands (NL) (629.37 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/nl/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_nl.pdf)

português (PT) (629.67 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/pt/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_pt.pdf)

Suomi (FI) (627.02 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/fi/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (630.14 KB - PDF)

**First published:**

01/06/2008

**Last updated:**

04/05/2023

[View](/sv/documents/all-authorised-presentations/neurobloc-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine NeuroBloc Active substance botulinum toxin type B International non-proprietary name (INN) or common name botulinum toxin type B Therapeutic area (MeSH) Torticollis Anatomical therapeutic chemical (ATC) code M03AX01

### Pharmacotherapeutic group

Muscle relaxants

### Therapeutic indication

NeuroBloc is indicated for the treatment of cervical dystonia (torticollis).

See section 5.1 for data on efficacy in patients responsive / resistant to botulinum toxin type A.

## Authorisation details

EMA product number EMEA/H/C/000301 Marketing authorisation holder

Sloan Pharma S.a.r.l

33 Rue du Puits Romain

Opinion adopted 19/10/2000 Marketing authorisation issued 22/01/2001 Revision 33

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

NeuroBloc : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1 MB - PDF)

**First published:** 25/08/2009

**Last updated:** 04/05/2023

[View](/en/documents/procedural-steps-after/neurobloc-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

NeuroBloc-H-C-PSUSA-00000428-201706 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

English (EN) (641.46 KB - PDF)

**First published:** 13/07/2018

**Last updated:** 04/05/2023

[View](/en/documents/scientific-conclusion/neurobloc-h-c-psusa-00000428-201706-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

NeuroBloc : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (675.7 KB - PDF)

**First published:** 01/06/2008

**Last updated:** 04/05/2023

[View](/en/documents/steps-after-cutoff/neurobloc-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

NeuroBloc : EPAR - Procedural steps taken before authorisation

English (EN) (659.8 KB - PDF)

**First published:** 01/06/2008

**Last updated:** 04/05/2023

[View](/en/documents/procedural-steps/neurobloc-epar-procedural-steps-taken-authorisation_en.pdf)

NeuroBloc : EPAR - Scientific Discussion

English (EN) (952.67 KB - PDF)

**First published:** 01/06/2008

**Last updated:** 04/05/2023

[View](/en/documents/scientific-discussion/neurobloc-epar-scientific-discussion_en.pdf)

**This page was last updated on** 04/05/2023

## Share this page

[Back to top](#main-content)